Prothena (PRTA) director receives 27,000 options at $9.76 strike

Rhea-AI Filing Summary

PROTHENA CORP PUBLIC LTD CO director Shane Cooke received a grant of stock options covering 27,000 Ordinary Shares. The options carry an exercise price of $9.76 per share and expire on May 15, 2036. This is a compensation-related award, not an open-market purchase.

According to the terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the grant date or the day of the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cooke Shane

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	27,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 27,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 27,000 options Exercise price: $9.76 per share Expiration date: May 15, 2036 +1 more

4 metrics

Options granted 27,000 options Stock Option (Right to Buy) grant to director Shane Cooke

Exercise price $9.76 per share Conversion or exercise price of the stock options

Expiration date May 15, 2036 Option term end date for the 27,000 options

Post-grant option holdings 27,000 options Total derivative securities owned following the transaction

Key Terms

Stock Option (Right to Buy), Ordinary Shares, exercise price, annual general meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"conversion_or_exercise_price: "9.7600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual general meeting financial

"on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cooke Shane

(Last) (First) (Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.76	05/15/2026		A		27,000		(1)	05/15/2036	Ordinary Shares	27,000	$0	27,000	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

	/s/ Michael J. Malecek, as Attorney-in-Fact for Shane Cooke	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Prothena (PRTA) director Shane Cooke report in this Form 4?

Shane Cooke reported receiving a grant of stock options for 27,000 Prothena Ordinary Shares. These options are part of his director compensation and give him the right to buy shares later at a fixed exercise price if vesting conditions are met.

How many Prothena (PRTA) shares are covered by Shane Cooke’s new options?

The option grant covers 27,000 Ordinary Shares of Prothena. Each option represents the right to buy one share, subject to vesting and exercisability conditions described in the award, providing potential future equity exposure if the options are eventually exercised.

What is the exercise price and expiration date of Shane Cooke’s Prothena options?

The options have an exercise price of $9.76 per share and expire on May 15, 2036. This means Cooke can choose to buy shares at $9.76 any time after vesting and before expiration, subject to the plan’s terms and his continued service.

When do Shane Cooke’s Prothena (PRTA) stock options vest?

All 27,000 options will vest 100% on the earlier of the first anniversary of the grant date or the day of Prothena’s 2027 annual general meeting. Vesting requires his continuous service as a director through that date, aligning the award with ongoing board service.

Is Shane Cooke’s Form 4 transaction a market purchase of Prothena shares?

No, this Form 4 reports a grant of stock options as compensation, not a market purchase of existing shares. The award gives him the right to buy Prothena shares later at $9.76 per share if he chooses to exercise after vesting.

How many Prothena options does Shane Cooke hold after this grant?

After this transaction, the filing shows Shane Cooke holding 27,000 stock options. These options are directly owned and relate to Prothena Ordinary Shares, reflecting his new option position following the grant recorded in this Form 4.